Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has had a turbulent couple of days of trading, but Echelon Wealth Partners … [Read more...] about Antibe Therapeutics is undervalued, Echelon analyst Loe says
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Shares of Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News TSX:MDNA) have skyrocketed over the past few months, but there’s … [Read more...] about Medicenna has lots left in the tank, says Bloom Burton
Mackie Research Capital analyst André Uddin ussued an update to clients Monday on Medexus Pharmaceuticals (Medexus Pharmaceuticals Stock Quote, Chart, … [Read more...] about Medexus Pharmaceuticals has price target trimmed at Mackie Research
In an update to clients last Friday, Stifel GMP analyst Justin Keywood said cardiovascular and central nervous system drug developer HLS Therapeutics … [Read more...] about HLS Therapeutics is undervalued, Stifel says
Stifel GMP analyst Justin Keywood released on Monday a flash update to clients, saying a new Health Canada decision has reinforced the status of HLS … [Read more...] about HLS Therapeutics is still a buy, Stifel Canada says
Investment bankers Paradigm Capital launched coverage on Wednesday of drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News … [Read more...] about Will Antibe Therapeutics break out in 2020?
With most stocks well off their 12-month highs, there are plenty of potential wins in the market these days, but for investors willing to set their … [Read more...] about Knight Therapeutics CEO Goodman is “brilliant”, this investor says
On the basis of extended timelines for clinical testing, Echelon Wealth Partners analyst Douglas Loe has lowered his price target on Theratechnologies … [Read more...] about Theratechnologies has price target cut at Echelon, keeps “Buy” rating
Is the cure for COVID-19 already out there? One of the consistent messages we have heard from the scientific community during the historic outbreak … [Read more...] about Is the cure for COVID-19 already out there?
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart, News TSXV:ATE) has performed well both over the past year and during the current market … [Read more...] about Antibe Therapeutics is a “Top Pick” at Echelon Wealth